학술논문
Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035
Document Type
Abstract
Author
Source
In Blood 16 November 2008 112(11):3224-3224
Subject
Language
ISSN
0006-4971